Potential Issue of Shares

BIOPHARMA CREDIT PLC

(THE "COMPANY")

POTENTIAL ISSUE OF SHARES

The Company is pleased to announce that, given the investments recently announced and the sizeable pipeline of near-term opportunities, it is considering an issue of ordinary shares prior to the end of January 2018. Any such issue would be for a total of up to 20% of the Company's total issued share capital and shares would be issued without a prospectus at a price not less than the most recently published NAV per share plus a premium to cover the costs of the issue. Any placing is likely to include participation by some cornerstone investors. Further details will be announced in due course.

Link Company Matters Limited

Company Secretary

11 December 2017

Enquiries:

Buchanan

David Rydell/Mark Court/ Jamie Hooper/ Henry Wilson

+44 (0) 20 7466 5000

Biopharmacredit@buchanan.uk.com

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27th March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

LEI: 213800AV55PYXAS7SY24